Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long-term survival

Eur J Heart Fail. 2023 Nov;25(11):2065-2066. doi: 10.1002/ejhf.3053. Epub 2023 Oct 18.

Authors

Alwin Tubben^{1

2}, Hans L A Nienhuis^{2

3}, Peter van der Meer^{1

2}

Affiliations

¹ Department of Cardiology, University Medical Centre Groningen, Groningen, The Netherlands.
² Amyloidosis Centre of Expertise, University Medical Centre Groningen, Groningen, The Netherlands.
³ Department of Internal Medicine, University Medical Centre Groningen, Groningen, The Netherlands.

PMID: 37792736
DOI: 10.1002/ejhf.3053

No abstract available

Publication types

Editorial
Comment

MeSH terms

Amyloid Neuropathies, Familial* / complications
Amyloid Neuropathies, Familial* / drug therapy
Cardiomyopathies* / complications
Cardiomyopathies* / drug therapy
Heart Failure* / drug therapy
Heart Failure* / etiology
Humans

Substances

tafamidis

Supplementary concepts

Amyloidosis, Hereditary, Transthyretin-Related